MIRCERA.com

MIRCERA is a continuous erythropoietin receptor activator (C.E.R.A.) and is the first approved, chemically synthesised erythropoiesis-stimulating agent (ESA). The active ingredient is methoxy polyethylene glycol-epoetin beta which differs from erythropoietin through formation of a chemical bond between either the N-terminal amino group or the e-amino group of any lysine present in erythropoietin and methoxy polyethylene glycol butanoic acid.¹ The average molecular weight is approximately 60kDa.¹

 

MIRCERA is indicated for the treatment of anaemia associated with chronic kidney disease. The safety and efficacy of MIRCERA therapy in other indications has not been established.²

 

References:

 

1. Macdougall IC, Eckardt K-U. Novel strategies for stimulating erythropoiesis and potential treatments for anaemia. Lancet. 2006;368:947–953.
2. MIRCERA® Summary of Product Characteristics. F. Hoffmann-La Roche Ltd. 2007.